New blood test could show if prostate cancer treatment is failing - The discovery could lead to personalised treatments for ...

Routine prostate cancer screening has been rejected by the UK's independent screening committee despite significant pressure ...

Tempus AI (NasdaqGS:TEM) has launched the ArteraAI Prostate Test, its first externally developed AI-powered digital pathology test for metastatic hormone-sensitive prostate cancer. The test is ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test at the end of this month. Prolaris will be the ...

Prostate-specific antigen (PSA) blood testing likely reduces the risk of death from prostate cancer, found a new review ...

Only men with a specific gene variant and a family history of certain cancers should be screened, experts have said.

Testing the molecular profile of tumors identifies which patients with advanced prostate cancer are more likely to benefit from chemotherapy and live longer, sparing patients less likely to benefit ...

Only men with a dangerous genetic variant and a family history of cancer should be offered screening, say UK advisors.

A new blood test could help doctors identify whether a treatment for advanced prostate cancer is failing weeks earlier than ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in ...